Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.7k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #643

    Tror faktisk, at de store partnerne er meget nidkære omkring kommunikationen omkring det de deltager i sammen med Genmab.

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #644

      Selvfølgelig er de det Helge. Det er jo ikke pebernødder det handler om. Industrispionage er vel også en del af Big Pharma.

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #645

        God morgen.:-)

        1 Reply Last reply
        0
        • B Offline
          B Offline
          bibob
          wrote on sidst redigeret af
          #646

          God Kristi Himmelfart. :-). Kunne vi bare få Genmab samme vej. 😉

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #647

            Tak bibob...Sidder og skriver på min kommende investeringsbog. Genmab får sit helt eget kapitel. 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #648

              yeah thks bibob.... the current mood here is more like "glad it is closed, so that it can't go to hell" 😉

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #649

                Only 1 Helge? 😉

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #650

                  this old Ofa
                  study has results posted - Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) - https://clinicaltrials.gov/ct2/history/NCT01191190?A=5&B=6&C=merged

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #651

                    The DRd vs Rd Study Completion date 2 years earlier (why would they do that?) - https://clinicaltrials.gov/ct2/history/NCT02252172?A=45&B=46&C=merged

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #652

                      Helge. Det må blive med rabat til PI. medlemmer. Man er vel Vendelbo. 😄

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #653

                        E L, in June last year they changed it from 2022 to 2024. Now they have changed it back to 2022. At the same time (June last year) they changed the end of study from maximum up to 5 years to 7 years. But as it is "up to" I guess they have now found out that the 7 years are not necessary.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #654

                          Study start 2015 + 7 = 2022

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #655

                            ok, thanks

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #656

                              Det bliver der bibob. 🙂

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                Mcjean
                                wrote on sidst redigeret af
                                #657

                                Yep 1 bog fuld pris, køb 100 spar 1 hel bogs værdi;-)

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #658

                                  April 10, 2018; 90 (15 Supplement) APRIL 27, 2018
                                  Anti-CD20 Antibodies Ofatumumab and Ocrelizumab Have Distinct Effects on Human B-cell Survival (S52.003)

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #659

                                    the extent of cell lysis was highest with ofatumumab, followed by rituximab and ocrelizumab. Ongoing studies in other B-cell cytotoxicity assays will provide a broader overview regarding relevant MoAs.

                                    Conclusions: The strong complement-dependent B-cell lysis by ofatumumab may contribute to its high potency in vivo that enables a low-dose subcutaneous dosing regimen.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #660

                                      Fint, tak gentogen

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #661

                                        EMA:
                                        The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:
                                        • Daratumumab, EMEA-002152-PIP01-17, from Janssen-Cilag International N.V., for the treatment of lymphoid malignancies (except mature B-cell neoplasms); http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2018/05/WC500248882.pdf

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #662

                                          Recommendations for submission of supplementary information for Dara, signal Encephalopathy, to Assess in the next PSUR (submission by 24 July 2018) - http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation_on_signal/2018/04/WC500247424.pdf p8

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger